Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Biotech
UPDATE: Amgen axes an obesity asset, zooms in on MariTide
Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide.
Gabrielle Masson
May 2, 2024 6:16pm
Lonza lands new CEO—Chutes & Ladders
Apr 5, 2024 8:30am
Gilead bets $1.5B-plus on Merus' trispecifc T-cell engagers
Mar 6, 2024 10:02am
Frontier CEO weathers one of his hardest fundraises to add $80M
Feb 22, 2024 4:01pm
GLP-1 enthusiasm pushes BioAge into new age with $170M series D
Feb 13, 2024 8:00am
Amgen's obesity drug may help patients keep the weight off
Feb 7, 2024 10:40am